Last €34.10 EUR
Change Today +0.76 / 2.26%
Volume 58.8K
IPN On Other Exchanges
Symbol
Exchange
EN Paris
OTC US
OTC US
Stuttgart
As of 11:35 AM 07/11/14 All times are local (Market data is delayed by at least 15 minutes).

ipsen (IPN) Snapshot

Open
€33.40
Previous Close
€33.35
Day High
€34.10
Day Low
€33.40
52 Week High
05/29/14 - €37.13
52 Week Low
09/16/13 - €26.33
Market Cap
2.8B
Average Volume 10 Days
56.6K
EPS TTM
€1.71
Shares Outstanding
82.8M
EX-Date
06/9/14
P/E TM
19.9x
Dividend
€0.80
Dividend Yield
2.35%
Current Stock Chart for IPSEN (IPN)

Related News

No related news articles were found.

ipsen (IPN) Related Businessweek News

View More BusinessWeek News

ipsen (IPN) Details

Ipsen S.A. operates as a pharmaceutical company worldwide. It offers drugs in the areas of uro-oncology, endocrinology, neurology, gastroenterology, cardiovascular, and cognitive disorders. The company’s products include Decapeptyl, a peptide formulation for injection in the treatment of advanced prostate cancer; Hexvix that is used to enhance detection of bladder cancer; and Somatuline and Somatuline Autogel, which are used in the treatment of acromegaly and neuroendocrine tumours. Ipsen S.A. also offers NutropinAq, a liquid formulation used in the treatment of growth failure in children and growth hormone deficiency in adults; Increlex, a formulation used for the long-term treatment of growth failure in children and adolescents with severe primary insulin-like growth factor 1 deficiency; and Dysport, a botulinum neurotoxin type A complex used to treat spasticity of upper limbs following a stroke, as well as the spasticity of other muscles. In addition, it provides Smecta, a natural clay-based drug used in the treatment of chronic and acute diarrhea; Forlax, a drug based on a linear polyethylene glycol polymer used in the treatment of constipation; and Tanakan that is used in the treatment of age-related cognitive disorders. Further, the company offers Nisis and Nisisco oral formulations containing valsartan used in the treatment of hypertension; and Adenuric for the treatment of gout. Additionally, it is developing products in the areas of neurology, endocrinology, and uro-oncology, including BN82451, Tasquinimod, Somatuline Autogel, Dysport, Dysport Next Generation, and Decapeptyl. The company was founded in 1929 and is headquartered in Boulogne-Billancourt, France. Ipsen S.A. is a subsidiary of Mayroy S.A.

4,602 Employees
Last Reported Date: 03/26/14
Founded in 1929

ipsen (IPN) Top Compensated Officers

Chairman, Chief Executive Officer and Member ...
Total Annual Compensation: €1.4M
Deputy Chief Executive Officer and Interim Ex...
Total Annual Compensation: €1.1M
Compensation as of Fiscal Year 2013.

ipsen (IPN) Key Developments

Ipsen S.A. Announces Supplemental New Drug Application Submitted to the U.S. Food and Drug Administration

Ipsen S.A. announced that it has submitted a Supplemental New Drug Application to the U.S. Food and Drug Administration (FDA) for Somatuline(R) Depot 120mg injection for the treatment of gastroenteropancreatic neuroendocrine tumors. In the European Union, Ipsen has submitted national marketing authorization variations for Somatuline(R) Autogel(R) 120mg injection to the drug regulatory authorities in 25 countries of the European Union. Regulatory submission is supported by the results of the CLARINET(R) Phase III study, which demonstrated the antiproliferative effect of Somatuline(R) in the treatment of patients with GEP-NETs. The data from CLARINET(R) showed that investigational treatment with Somatuline(R) substantially prolonged time to disease progression or death versus placebo (hazard ratio 0.47, p=0.0002). Safety data generated from the CLARINET(R) study were consistent with the known safety profile of Somatuline. The data from CLARINET(R) is purely investigational, as Somatuline(R) is not authorized for the indication of antiproliferative treatment of gastroenteropancreatic neuroendocrine tumors (GEP-NETs) in any market. In many countries where it is marketed as Somatuline(R) Autogel(R), Somatuline(R) is approved for treatment of acromegaly and for the symptoms associated with neuroendocrine tumors, which can include the treatment of GEP-NET patients experiencing symptoms from carcinoid syndrome, and Somatuline(R) is approved in many countries for the treatment of acromegaly. Somatuline(R) Depot is approved in the US for the treatment of acromegaly but not for the treatment of GEP-NETs or the symptoms thereof.

Ipsen Announces Unaudited Consolidated Sales Results for the First Quarter of 2014

Ipsen announced unaudited consolidated sales results for the first quarter of 2014. For the quarter, the company posted that sales decline of 0.2% year on year to EUR 305.9 million from EUR 306.6 million on 2013. However, the sales decline was impacted by adverse foreign exchange as net sales change compared to the first quarter of 2013 at constant exchange rates registered an increase by 2.4% year on year.

Ipsen S.A. Presents at UBS Global Healthcare Conference, May-19-2014

Ipsen S.A. Presents at UBS Global Healthcare Conference, May-19-2014 . Venue: Sheraton New York Times Square Hotel, 811 Seventh Avenue, New York, New York, United States.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
IPN:FP €34.10 EUR +0.76

IPN Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Almirall SA €10.81 EUR -0.19
Meda AB kr114.10 SEK -0.20
Orion OYJ €26.77 EUR +0.33
Procter & Gamble Hygiene & Health Care Ltd 4,551 INR -122.85
Recordati SpA €12.58 EUR +0.27
View Industry Companies
 

Industry Analysis

IPN

Industry Average

Valuation IPN Industry Range
Price/Earnings 19.4x
Price/Sales -- Not Meaningful
Price/Book 2.8x
Price/Cash Flow 17.4x
TEV/Sales 2.0x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact IPSEN, please visit www.ipsen.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.